Q-omics provides the consensus-scored UNC5B profile across patient tissues and cancer cell-line models. UNC5B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, UNC5B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, UNC5B RNA expression shows 18,934 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where UNC5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC5B survival associations across molecular data types. UNC5B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC5B RNA expression–survival associations across cancer types. High UNC5B expression shows unfavorable associations in KIRP, OV, LIHC, MESO and LGG, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for UNC5B RNA expression.
This table summarizes UNC5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UNC5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC5B shows lower tumor expression in COAD and higher tumor expression in KIRC, THCA, HNSC, LIHC and BRCA. The KIRC box plot shows higher UNC5B RNA expression in tumor versus normal tissue (log2 FC = +1.939, t-test p < 0.001).
This table shows molecular features associated with UNC5B in patient tissues and cancer cell lines. In patient samples, UNC5B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UNC5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
